OncoCyte Corporation (OCX) Social Stream
Oncocyte Corp (OCX) Price Targets From Analysts
Use the tables below to see what analysts covering Oncocyte Corp think about its future price and what recommendations they have for investors and traders.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-09 | 3 | $11 | $5 | $7.75 | $1.49 | 420.13% |
| 2021-11-10 | 3 | $11 | $7 | $8.333 | $1.49 | 459.26% |
| 2021-12-16 | 3 | $11 | $5 | $7.666 | $1.49 | 414.5% |
| 2022-01-06 | 5 | $11 | $3.1 | $6.525 | $1.49 | 337.92% |
| 2022-02-01 | 5 | $11 | $3.1 | $5.84 | $1.49 | 291.95% |
| 2022-03-17 | 5 | $11 | $1.8 | $5.225 | $1.49 | 250.67% |
The Trend in the Analyst Price Target
OCX's average price target has moved down $2.53 over the prior 128 days.
OCX reports an average of 112.98% for its upside potential over the past 50 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-04-17 | 1 | 11 | 2.0 | 7.710 | 4.80 | 60.63% |
| 2021-07-17 | 1 | 11 | 7.0 | 8.830 | 5.30 | 66.6% |
| 2021-11-10 | 4 | 11 | 7.0 | 8.333 | 3.35 | 148.75% |
| 2022-01-06 | 5 | 11 | 3.1 | 6.525 | 2.06 | 216.75% |
| 2022-02-01 | 5 | 11 | 3.1 | 5.840 | 1.75 | 233.71% |
OCX Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.6 | 3 | 1 | 1 | 0 | 0 | 5 |
The Trend in the Broker Recommendations
OCX's average broker recommendation rating worsened by 0.6 over the prior 21 months.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- OCX has a greater average analyst price target than 46.37% of all US stocks.
- Oncocyte Corp's upside potential (average analyst target price relative to current price) is higher than 843.33% of all US stocks.
- In terms of how Oncocyte Corp fares relative to stocks in the small market cap category, note that its variance in analysts' estimates is lower than -668.9% of that group.
- OCX has a greater number of analysts covering the stock than 230.63% of Healthcare stocks.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to Oncocyte Corp are NAVB, LHDX, and AWH.
Is OCX a Buy, Hold or Sell? See the POWR Ratings now!